Coherus Oncology (NASDAQ: CHRS ) has demonstrated more compelling revenue growth from Loqtorzi (toripalimab) with Q2 2025 earnings than it did in Q1 2025 and is inching closer to major readouts from its developmental pipeline. I rated CHRSScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s Disclosure ...